Notícias e Atividades da Cybin

Fusão, aquisição e financiamento envolvendo Cybin.

• Cybin adquiriu Small Pharma (publicado em 24 de outubro de 2023).

Veja o organograma con seus 31 executivos principais

Biografias mais buscadas da Cybin

• Doug Drysdale, Chief Executive Officer
• Mark Lawson, Director
• Eric Hoskins, Director

Recentes movimentos de executivos em Cybin

• Mirza Rahman, ingressou na Companhia como Senior Vice President, Patient Safety and Pharmacovigilance  (Notícia publicada em 2 de outubro de 2024).
• Marcelo Gutierrez, ingressou na Companhia como Vice President, Clinical Pharmacology  (Notícia publicada em 2 de outubro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Cybin.

Cybin possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Cybin

• Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
• Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
• Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
• Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
• Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
• Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
• Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
• Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
• Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
• Cybin to Participate at the 2024 Milken Institute Future of Health Summit
• View more press releases Close

Redes sociais sobre Cybin

• Cybin na Wikipedia, Google News e Yahoo Finance
• Cybin na LinkedIn, Twitter e YouTube